132 related articles for article (PubMed ID: 38052709)
21. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
Hungria V; Beksac M; Weisel KC; Nooka AK; Masszi T; Spicka I; Munder M; Mateos MV; Mark TM; Qi M; Qin X; Fastenau J; Spencer A; Sonneveld P; Garvin W; Renaud T; Gries KS
Br J Haematol; 2021 May; 193(3):561-569. PubMed ID: 33555030
[TBL] [Abstract][Full Text] [Related]
22. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV; Chari A; Usmani SZ; Goldschmidt H; Weisel K; Qi K; Londhe A; Nair S; Lin X; Pei L; Ammann E; Kobos R; Smit J; Parekh T; Marshall A; Slavcev M; Moreau P
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):385-393. PubMed ID: 36967244
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Weisel K; Dimopoulos M; Moreau P; Yagci M; Larocca A; Kanate AS; Vural F; Cascavilla N; Basu S; Johnson P; Byeff P; Hus M; Rodríguez-Otero P; Muelduer E; Anttila P; Hayden PJ; Krauth MT; Lucio P; Ben-Yehuda D; Mendeleeva L; Guo S; Yu X; Grote L; Biyukov T; Dhanasiri S; Richardson P
Leuk Lymphoma; 2020 Aug; 61(8):1850-1859. PubMed ID: 32268815
[TBL] [Abstract][Full Text] [Related]
25. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
26. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m
Moreau P; Kumar S; Boccia R; Iida S; Goldschmidt H; Cocks K; Trigg A; Zahlten-Kumeli A; Yucel E; Panjabi SS; Dimopoulos M
Leukemia; 2019 Dec; 33(12):2934-2946. PubMed ID: 31092895
[TBL] [Abstract][Full Text] [Related]
27. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Cella D; McKendrick J; Kudlac A; Palumbo A; Oukessou A; Vij R; Zyczynski T; Davis C
Ann Hematol; 2018 Dec; 97(12):2455-2463. PubMed ID: 30178193
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Larocca A; Leleu X; Touzeau C; Bladé J; Paner A; Mateos MV; Cavo M; Maisel C; Alegre A; Oriol A; Raptis A; Rodriguez-Otero P; Mazumder A; Laubach J; Nadeem O; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG
Br J Haematol; 2022 Feb; 196(3):639-648. PubMed ID: 34671975
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract][Full Text] [Related]
30. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
[TBL] [Abstract][Full Text] [Related]
31. The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies.
Ojo AS; Araoye MO; Ali A; Sarma R
J Cancer Surviv; 2024 Jun; 18(3):673-697. PubMed ID: 36645615
[TBL] [Abstract][Full Text] [Related]
32. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
[TBL] [Abstract][Full Text] [Related]
33. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
[TBL] [Abstract][Full Text] [Related]
35. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
36. A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Efficace F; Boccadoro M; Palumbo A; Petrucci MT; Cottone F; Cannella L; Zamagni E; Niscola P; Kyriakou C; Caravita T; Offidani M; Mandelli F; Cavo M
Health Qual Life Outcomes; 2018 Jun; 16(1):127. PubMed ID: 29914509
[TBL] [Abstract][Full Text] [Related]
37. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA; Luke JJ; Long GV; Ascierto PA; Rutkowski P; Schadendorf D; Robert C; Grob JJ; de la Cruz Merino L; Del Vecchio M; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Carlino MS; Mohr P; De Galitiis F; Ross MI; Eroglu Z; Chen K; Jiang R; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Kirkwood JM
Eur J Cancer; 2022 Nov; 176():207-217. PubMed ID: 36202690
[TBL] [Abstract][Full Text] [Related]
39. Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
Popat R; Lonial S; Voorhees PM; Esposti SD; Gorsh B; Gupta I; Opalinska J; Sapra S; Piontek T; He Z; Kleinman D; Schaumberg D; Regnault A; Meunier J; Eliason L
J Adv Pract Oncol; 2023 Sep; 14(6):503-518. PubMed ID: 37808071
[TBL] [Abstract][Full Text] [Related]
40. Teclistamab-cqyv in multiple myeloma.
Martino EA; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
Eur J Haematol; 2024 Mar; 112(3):320-327. PubMed ID: 37848191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
